

Megakaryon




*Induced pluripotent stem cells

Target : Megakaryon Corporation

Outline : Development of platelet preparations using human induced pluripotent stem (hiPS) cells

(The platelet-preparation technology is not reliant on donated blood. It (1) can produce a stable supply of platelets, (2) has a high safety profile, and (3) makes low-medical-cost blood transfusions possible)

Authorized investment : ¥3 billion (maximum)



- One of a small number of venture companies taking up the challenge of commercialization in the field of iPS cells, in which Japan is a world leader
- Artificially produced platelet preparations can overcome supply constraints and the risk of viral infection associated with dependence on donated blood